The introduction of oxaliplatin as adjuvant treatment for stage III colon cancer in 2004 has been the last practice changing progress in adjuvant treatment for patients with early colon cancer. Since then, many prognostic and predictive biomarkers have been studied, but only DNA mismatch repair status has been validated as having an important prognostic value. Accordingly, TNM and clinical-pathological patterns, such as pT4 lesions and lymph node sampling <12 nodes, are the main factors that guide physicians' choice regarding adjuvant treatment. More recently, many biomarkers showed promising results: POLE, ErbB2, CDX2, SMAD4, BRAF and KRAS. In addition to these, immune-contexture, molecular classification, and gene signatures could become new ways to better classify colon cancer patients with more discriminatory power than TNM. The aim of this review is to report the state-of-the-art of prognostic and predictive factors in the adjuvant setting and which of these could modify clinical practice and maybe replace TNM classification.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489295 | PMC |
| http://dx.doi.org/10.1007/s11523-017-0494-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Susceptibility of different mice species to chemical induction of colorectal cancer by 1,2-dimethylhydrazine.
J Egypt Natl Canc Inst
January 2025
Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.
Background: Colorectal cancer (CRC) is a major public health concern. Animal models play a crucial role in understanding the disease pathology and development of effective treatment strategies. Chemically induced CRC represents a cornerstone in animal model development; however, due to the presence of different animal species with different genetic backgrounds, it becomes mandatory to study the susceptibility of different mice species to CRC induction by different chemical entities such as 1,2-dimethylhydrazine (DMH).
View Article and Find Full Text PDFAlginate coated mesoporous silica nanoparticles as oral delivery carrier of curcumin and quercetin to colon cancer: preparation, optimization, characterization, and anticancer activity.
Drug Deliv Transl Res
January 2025
Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200, Kepala Batas, Penang, Malaysia.
The synergistic bioactive effect of polyphenols can enhance the development of functional foods to prevent chronic diseases such as cancer. Curcumin and quercetin have been shown to possess anticancer properties. The combination of curcumin and quercetin has been shown to provide synergistic effects against cancer cell proliferation.
View Article and Find Full Text PDFCancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy.
J Immunother Cancer
January 2025
Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
Background: CD3 bispecific antibody (CD3 bsAb) therapy has become an established treatment modality for some cancer types and exploits endogenous T cells irrespective of their specificity. However, durable clinical responses are hampered by immune escape through loss of tumor target antigen expression. Induction of long-lasting tumor-specific immunity might therefore improve therapeutic efficacy, but has not been studied in detail yet for CD3 bsAbs.
View Article and Find Full Text PDFQuality of Gastrointestinal Surgical Oncology Care According to Insurance Status.
J Gastrointest Surg
January 2025
Division of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, CT. Electronic address:
Background: Despite efforts to expand insurance coverage, substantial inequalities persist, particularly in cancer treatment. We aimed to evaluate whether quality disparities exist across major insurance plans for patients undergoing curative-intent resection for gastrointestinal (GI) cancers.
Methods: This is a retrospective study of adult patients in the National Cancer Database (NCDB) diagnosed with GI malignant neoplasms between January 1, 2004 and December 31, 2020.
Analysis of Departures from Linearity in the Dose Response for Japanese Atomic Bomb Survivor Solid Cancer Mortality and Cancer Incidence Data and Assessment of Low-Dose Extrapolation Factors.
Radiat Res
January 2025
Chief (retired), Department of Statistics, Radiation Research Effects Foundation, Hiroshima, Japan.
Although leukemia in the Japanese atomic bomb survivor data has long exhibited upward curvature, until recently this appeared not to be the case for solid cancer. It has been suggested that the recently observed upward curvature in the dose response for the Japanese atomic bomb survivor solid cancer mortality data may be accounted for by flattening of the dose response in the moderate dose range (0.3-0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!